Novavax Covid Vaccine Highly Effective, But Not Against South Africa Variant


2021-01-29 00:29:09

Novavax Covid Vaccine Highly Effective, But Not Against South Africa Variant

Novavax said it began working on new vaccines against emerging strains in early January.

Washington, United States:

US biotech firm Novavax said Thursday its two-shot Covid-19 vaccine showed an overall efficacy of 89.3 percent in a major Phase 3 clinical trial in Britain, and remained highly effective against a variant first identified there.

But the positive news was partly offset by other results that showed it offered significantly less protection against a highly transmissible variant of the coronavirus first identified in South Africa, which is spreading rapidly around the world.

Novavax said it began working on new vaccines against emerging strains in early January and expects to select ideal candidates in the coming days, then begin clinical testing in the second quarter of the year.

“NVX-CoV2373 has the potential to play an important role in solving this global public health crisis,” said the company’s president and CEO Stanley Erck, using Novavax’s name for the vaccine.

“We look forward to continuing to work with our partners, collaborators, investigators and regulators around the world to make the vaccine available as quickly as possible.”

British Prime Minister Boris Johnson tweeted that the results were “good news.”

“Our medicines regulator will now assess the vaccine, which will be made in Teesside. If approved, we have 60m doses on order,” he added.

The vaccine was one of six candidates backed by a US government project formerly known as Operation Warp Speed, which has provided the company $1.75 billion. It’s also being tested in a trial in the US and Mexico, which has recruited 16,000 of 30,000 participants.

Unlike the Pfizer, Moderna and AstraZeneca vaccines, which deliver the genetic instructions that make human cells create a key protein of the virus, the Novavax shot injects the proteins directly into the body to evoke an immune response.

“Still pretty good” against B.1.351

The British trial involved 15,000 people aged 18 to 84, including 27 percent who were over the age of 65.

The first interim analysis was based on 62 cases, of which 56 cases of Covid-19 were observed in the placebo group versus six cases among people who received NVX-CoV2373.

The company’s preliminary analysis indicated the variant first identified in Britain, B.1.1.7, was detected in more than 50 percent of the confirmed cases.

Efficacy by strain was calculated at 95.6 percent against the original Covid strain, and 85.6 percent against B.1.1.7.

Newsbeep

But the level of protection was lower in a smaller, mid-stage trial conducted in South Africa.

This study enrolled just over 4,400 patients from September to mid-January, during which time the B.1.351 variant, which contains critical mutations along the virus’ spike protein, was spreading rapidly through the country.

Overall efficacy was 49.4 percent in this trial, but the figure rose to 60 percent among the 94 percent of trial participants who were HIV-negative.

Worryingly, Novavax said about a third of participants in the South Africa trial had been previously infected with the original form of the virus, while the subsequent infections during the study were largely from the variant.

Amesh Adalja, a doctor and senior scholar at the Johns Hopkins Center for Health Security, told AFP it was important to keep the decreased efficacy in perspective and the vaccine was still a success.

“Sixty percent against the variant is still pretty good,” he said. “Clearly, the Novavax vaccine prevented severe disease which is really in the end what matters the most.”

J&J next?

The studies are the first to assess a Covid-19 vaccine’s performance against both the UK and South Africa variants in the real world.

Pfizer and Moderna have previously said their vaccines remain effective against the variants, but their studies were based on lab research.

The US said Thursday it had found its first two cases of the B.1.351 variant on American soil, leading to concern it could reignite the national infection rate, which is currently in decline.

Novavax’s announcement puts pressure on another vaccine maker, Johnson & Johnson, which is expected to announce its phase 3 trial results next week.

(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)



Source link

78 Comments

  1. Nncssnopy February 3, 2021
  2. FqhhGroom February 4, 2021
  3. KuikEvows February 6, 2021
  4. Fvfcsnopy February 7, 2021
  5. AhkdGroom February 8, 2021
  6. KbcxZece February 8, 2021
  7. JbbvGroom February 9, 2021
  8. Jbnbsting February 10, 2021
  9. FqbbGroom February 11, 2021
  10. Nbnhsnopy February 11, 2021
  11. KbbfEvows February 13, 2021
  12. LabxGroom February 14, 2021
  13. KvaxZece February 16, 2021
  14. AhbzGroom February 16, 2021
  15. JbbnGroom February 17, 2021
  16. Jbnvsting February 17, 2021
  17. Nbmosnopy February 26, 2021
  18. KndnZece March 2, 2021
  19. WesleyUtiff March 5, 2021
  20. MarcosEtess March 5, 2021
  21. Randyabemi March 8, 2021
  22. Michaelhom March 8, 2021
  23. Randyabemi March 9, 2021
  24. Michaelhom March 9, 2021
  25. Wayneweday March 11, 2021
  26. JeffreyGog March 11, 2021
  27. Wayneweday March 12, 2021
  28. JeffreyGog March 12, 2021
  29. JeffreyGog March 13, 2021
  30. Wayneweday March 14, 2021
  31. JeffreyGog March 14, 2021
  32. Wayneweday March 14, 2021
  33. JeffreyGog March 15, 2021
  34. Wayneweday March 15, 2021
  35. Ricardomus March 16, 2021
  36. Stanleycak March 16, 2021
  37. Ricardomus March 17, 2021
  38. Stanleycak March 17, 2021
  39. Ricardomus March 18, 2021
  40. ThomasHaf March 18, 2021
  41. Ricardomus March 19, 2021
  42. ThomasHaf March 19, 2021
  43. Ricardomus March 20, 2021
  44. ThomasHaf March 20, 2021
  45. MarvinHag March 22, 2021
  46. ElmerJearo March 22, 2021
  47. MarvinHag March 23, 2021
  48. ElmerJearo March 23, 2021
  49. MarvinHag March 25, 2021
  50. Jasoncok March 25, 2021
  51. MarvinHag March 26, 2021
  52. Jasoncok March 27, 2021
  53. MarvinHag March 27, 2021
  54. MarvinHag March 28, 2021
  55. Jasoncok March 29, 2021
  56. VictorJonge March 29, 2021
  57. Scottrhync March 30, 2021
  58. VictorJonge March 30, 2021
  59. Scottrhync March 31, 2021
  60. VictorJonge March 31, 2021
  61. Frankhem April 1, 2021
  62. Scottrhync April 1, 2021
  63. Frankhem April 2, 2021
  64. Scottrhync April 3, 2021
  65. Charlesget April 4, 2021
  66. Stevenstazy April 5, 2021
  67. Charlesget April 5, 2021
  68. Stevenstazy April 6, 2021
  69. Charlesget April 6, 2021
  70. Alfredted April 7, 2021
  71. BillyViz April 7, 2021
  72. Alfredted April 8, 2021
  73. BillyViz April 8, 2021
  74. Alfredted April 9, 2021
  75. BillyViz April 9, 2021
  76. HarryShife April 10, 2021
  77. HarryShife April 10, 2021
  78. JamesBrivy April 11, 2021

Leave a Reply